Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 23
Filter
Add more filters










Publication year range
1.
Gene Ther ; 12(1): 67-74, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15385952

ABSTRACT

Lentiviral vectors have turned out to be an efficient method for stable gene transfer in vitro and in vivo. Not only do fields of application include cell marking and tracing following transplantation in vivo, but also the stable delivery of biological active proteins for gene therapy. A variety of cells, however, need immediate transplantation after preparation, for example, to prevent cell death, differentiation or de-differentiation. Although these cells are usually washed several times following lentiviral transduction, there may be the risk of viral vector shuttle via transplanted cells resulting in undesired in vivo transduction of recipient cells. We investigated whether infectious lentiviral particles are transmitted via ex vivo lentivirally transduced cells. To this end, we explored potential viral shuttle via ex vivo lentivirally transduced cardiomyocytes in vitro and following transplantation into the brain and peripheral muscle. We demonstrate that, even after extensive washing, infectious viral vector particles can be detected in cell suspensions. Those lentiviral vector particles were able to transduce target cells in transwell experiments. Moreover, transmitted vector particles stably transduced resident cells of the recipient central nervous system and muscle in vivo. Our results of lentiviral vector shuttle via transduced cardiomyocytes are significant for both ex vivo gene therapy and for lentiviral cell tracing, in particular for investigation of stem cell differentiation in transplantation models and co-cultivation systems.


Subject(s)
Cell Transplantation , Genetic Therapy/adverse effects , Genetic Vectors/administration & dosage , Lentivirus Infections/transmission , Lentivirus/genetics , Animals , Cell Line , Fibroblasts/virology , Genetic Therapy/methods , Genetic Vectors/genetics , Humans , Immunohistochemistry , Myocytes, Cardiac/virology , Rats , Rats, Wistar , Transduction, Genetic/methods
2.
Zentralbl Neurochir ; 65(4): 191-4, 2004 Nov.
Article in English | MEDLINE | ID: mdl-15551184

ABSTRACT

UNLABELLED: A 47-year-old man was admitted to our hospital with a nine-week history of visual disturbance, headache, disorientation and facial nerve palsy. Serial cranial magnetic resonance imaging (MRI) revealed progressive bilateral occipital edema with hemorrhage and meningeal involvement. There were no hints of hereditary or acquired immunodeficiency. Laboratory examination for bacterial and viral causes was negative. Open brain biopsy revealed primary central nervous system lymphoma of the extraordinary rare so-called "peripheral" T-cell type. The further course was fatal; the patient died 10 weeks after the onset of symptoms from tumor progression before planned chemotherapy could be started. CONCLUSION: If primary central nervous system lymphoma (PCNSL) is suspected, brain biopsy -- either open biopsy or stereotactic biopsy -- should be performed straight away to enable a rapid start of chemotherapy and/or radiotherapy. Peripheral T-cell lymphoma was highly aggressive in this case leading to the patient's death within several weeks.


Subject(s)
Central Nervous System Neoplasms/pathology , Lymphoma, T-Cell/pathology , Biopsy , Brain Edema/complications , Brain Edema/diagnostic imaging , Brain Edema/etiology , Central Nervous System Neoplasms/complications , Central Nervous System Neoplasms/diagnostic imaging , Cerebral Hemorrhage/complications , Cerebral Hemorrhage/diagnostic imaging , Cerebral Hemorrhage/etiology , Fatal Outcome , Humans , Immunohistochemistry , Lymphoma, T-Cell/complications , Lymphoma, T-Cell/diagnostic imaging , Magnetic Resonance Imaging , Male , Middle Aged , Radiography
3.
Gene Ther ; 9(24): 1708-14, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12457285

ABSTRACT

Lentiviral vectors have been shown to stably transduce dividing and non-dividing target cells in vitro and in vivo. However, in vivo gene transfer applications with viral vectors in the central nervous system require highly efficient vector preparations, because only very small volumes can be injected stereotactically without damage to the brain tissue. Since lentiviral vectors are generated in transient co-transfection systems, viral preparations need to be purified and efficiently concentrated before injection into the brain. We describe an alternative procedure to concentrate lentiviral preparations by binding viral particles to an anion exchange column. Viral particles are eluted with sodium chloride, desalted and further concentrated by ultrafiltration. These vector preparations allowed high levels of gene transfer into terminally differentiated neuronal and glial cells and long-term transgene expression without any signs of acute and long-term toxicity or inflammation. The purification of lentiviral vectors from large-scale preparations by anion exchange chromatography allowed us to concentrate the virus to small volumes and to use these preparations to genetically modified target cells in vivo without signs of acute inflammatory responses.


Subject(s)
Brain/metabolism , Genetic Vectors/isolation & purification , Lentivirus/genetics , Transduction, Genetic/methods , Animals , Cells, Cultured , Chromatography, Ion Exchange , Female , Genetic Vectors/administration & dosage , Genetic Vectors/genetics , Green Fluorescent Proteins , Luminescent Proteins/analysis , Luminescent Proteins/genetics , Neuroglia/metabolism , Neurons/metabolism , Rats , Rats, Inbred F344
4.
Br J Anaesth ; 88(3): 438-40, 2002 Mar.
Article in English | MEDLINE | ID: mdl-11990280

ABSTRACT

Neurological deterioration from intraspinal haematoma following insertion of a spinal needle is extremely rare. We present the case of a 28-yr-old female, who presented with complete paraplegia following attempted spinal anaesthesia for delivery of her third child. Space-occupying iatrogenic spinal haemorrhage from a previously undiagnosed lumbar ependymoma was found to be the precipitating cause. Following laminotomy with blood clot and tumour removal her neurological function improved.


Subject(s)
Anesthesia, Obstetrical/adverse effects , Anesthesia, Spinal/adverse effects , Ependymoma/complications , Paraplegia/etiology , Pregnancy Complications, Neoplastic , Spinal Neoplasms/complications , Adult , Female , Humans , Pregnancy
5.
Acta Neurochir (Wien) ; 144(2): 181-7, 2002 Feb.
Article in English | MEDLINE | ID: mdl-11862519

ABSTRACT

The cochlear nerve of adult Lewis rats was following microsurgical exposure in the cerebellopontine angle (CPA). The lesions completely interrupted the auditory nerve axons at the lesion site producing ipsilateral deafness in all animals. The rats were then treated with a recombinant Fab fragment of the antibody IN-1 against nerve growth inhibitory proteins for one to two weeks. An age-matched control group of rats was treated with unspecific mouse IgG antibody. Because the cochlear nerve lesions resulted in significant neuronal apoptosis of spiral ganglion cells, neurotrophin-3 (NT-3) was applied to the lesion site immediately post-injury in some rats. Electrophysiological studies were carried out by recording the brainstem auditory evoked potentials (BAEP) before and immediately after the lesion, and at regular intervals up to 2 months after injury. Cochlear nerve fibres were anterogradely traced by horseradish peroxidase (HRP) or biotinylated dextran amine (BDA) injected into the spiral ganglion. The results achieved in this study were consistent with the following conclusions: 1) transection of the adult rat cochlear nerve at the CPA results in functional deafness, disappearance of BAEP, apoptosis of parent axotomized neurons of the spiral ganglion, and interruption of labelled axons close to the lesion site; 2) NT-3 is able to partially rescue axotomized neurons of the spiral ganglion; 3) injured cochlear nerve fibres show a limited spontaneous sprouting and regrowth response which does not lead to BAEP recovery; 4) intrathecal treatment with IN-1 directed against myelin-associated neurite growth inhibitory proteins promotes significant elongation of the injured fibres; and 5) the regenerating fibres seem to navigate to correct targets, and be able to establish synaptic connections for functional recovery as depicted by BAEP examinations.


Subject(s)
Antibodies, Monoclonal/pharmacology , Cochlear Nerve/physiology , Evoked Potentials, Auditory, Brain Stem/physiology , Myelin Proteins/immunology , Animals , Antibodies, Monoclonal/administration & dosage , Apoptosis , Cochlear Nerve/immunology , Cochlear Nerve/pathology , Immunoglobulin Fab Fragments , Injections, Spinal , Myelin Sheath , Nerve Fibers/physiology , Rats , Rats, Inbred Lew , Regeneration
7.
Biotechniques ; 31(3): 520, 522, 524, passim, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11570495

ABSTRACT

Here, we describe a quantitative, DNA-based, real-time PCR approach to determine the number of lentivirus particles that are present in vector preparations. In this approach, the minus strong-stop cDNA fragment that is present in viral capsids serves as template for PCR. Using this technology, we found that only 0.1%-1% of the virus particles that are present in vector preparations are infectious. The approach described here is rapid, reliable, and simple in concept and can be used to estimate both vector particles in supernatants and the number of infectious particles. Also, this approach can easily be adapted to a high-throughput system by using 96-well plates and a 2-h running time.


Subject(s)
Genetic Vectors , Lentivirus/genetics , Polymerase Chain Reaction/methods , Virion/isolation & purification , Green Fluorescent Proteins , Luminescent Proteins/genetics , Microscopy, Fluorescence , Plasmids/genetics , RNA, Viral/analysis , RNA, Viral/isolation & purification , Transfection , Virion/genetics
8.
Neurosurgery ; 48(6): 1269-75; discussion 1275-7, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11383729

ABSTRACT

OBJECTIVE: Significant numbers of patients experience intractable pain after brachial plexus root avulsions. Medications and surgical procedures such as amputation of the limb are often not successful in pain treatment. METHODS: Forty-seven patients with intractable pain after traumatic cervical root avulsions were treated with dorsal root entry zone coagulation between 1980 and 1998. The dorsal root entry zone coagulation procedure was performed 4 months to 12 years after the trauma, and patients were monitored for up to 18 years (average follow-up period, 14 yr). RESULTS: Immediately after surgery, 75% of patients experienced significant pain reduction; this value was reduced to 63% during long-term follow-up monitoring. Nine patients experienced major complications, including subdural hematomas (n = 2) and motor weakness of the lower limb (n = 7). Improved coagulation electrodes with thermistors that could produce smaller and more-accurate lesion sizes, which were introduced in 1989, significantly reduced the number of complications. CONCLUSION: Central deafferentation pain that persists and becomes intractable among patients with traumatic cervical root avulsions has been difficult to treat in the past. Long-term follow-up monitoring of patients who underwent the dorsal root entry zone coagulation procedure in the cervical cord indicated that long-lasting satisfactory relief is possible for the majority of individuals, with acceptable morbidity rates.


Subject(s)
Brachial Plexus/injuries , Electrocoagulation , Neurosurgical Procedures , Pain, Intractable/surgery , Palliative Care , Spinal Nerve Roots/injuries , Spinal Nerve Roots/surgery , Wounds and Injuries/surgery , Electrocoagulation/adverse effects , Electrocoagulation/methods , Female , Follow-Up Studies , Humans , Male , Neurosurgical Procedures/adverse effects , Radio Waves , Treatment Outcome
10.
Virology ; 291(2): 191-7, 2001 Dec 20.
Article in English | MEDLINE | ID: mdl-11878888

ABSTRACT

The improvement of gene transfer efficiency in growth-arrested cells using human immunodeficiency virus type 1 (HIV-1)-derived vectors led to the development of vectors derived from other members of the lentivirus family. Here we report the generation of a lentiviral vector derived from the apathogenic molecular virus clone SIVagm3mc of the simian immunodeficiency virus from African green monkeys (Cercocebus pygerythrus). Upon pseudotyping with the G-protein of vesicular stomatitis virus (VSV-G), the SIVagm-derived vector was shown to transduce proliferating and growth-arrested mammalian cell lines, including human cells. After in vivo inoculation into the striatum of the adult rat brain, the vector was shown to transduce terminally differentiated neurons and oligodendrocytes as well as quiescent and reactive astrocytes. Moreover, SIVagm transfer vector mRNA was efficiently packaged by HIV-1 vector particles. Homologous [SIV(SIV)] vectors generated by using the SIVagm-derived envelope glycoproteins allowed selective gene transfer into human CD4(+)/CCR5(+) cells. Thus, the SIVagm3mc-derived vector is a useful alternative to HIV-1-derived lentiviral vectors in somatic gene therapy.


Subject(s)
Genetic Vectors , Membrane Glycoproteins , Simian Immunodeficiency Virus , Animals , CD4-Positive T-Lymphocytes , Cell Division , Cell Line, Transformed , Female , Genes, env , Genetic Vectors/genetics , HIV-1/genetics , Humans , Lentivirus/genetics , Neuroglia , Neurons , Rats , Rats, Inbred F344 , Simian Immunodeficiency Virus/genetics , Simian Immunodeficiency Virus/pathogenicity , Transduction, Genetic , Vesicular stomatitis Indiana virus/genetics , Viral Envelope Proteins/genetics , Virion
11.
J Virol ; 72(10): 8150-7, 1998 Oct.
Article in English | MEDLINE | ID: mdl-9733856

ABSTRACT

We have constructed a new series of lentivirus vectors based on human immunodeficiency virus type 1 (HIV-1) that can transduce nondividing cells. The U3 region of the 5' long terminal repeat (LTR) in vector constructs was replaced with the cytomegalovirus (CMV) promoter, resulting in Tat-independent transcription but still maintaining high levels of expression. A self-inactivating (SIN) vector was constructed by deleting 133 bp in the U3 region of the 3' LTR, including the TATA box and binding sites for transcription factors Sp1 and NF-kappaB. The deletion is transferred to the 5' LTR after reverse transcription and integration in infected cells, resulting in the transcriptional inactivation of the LTR in the proviruses. SIN viruses can be generated with no significant decreases in titer. Injection of viruses into the rat brain showed that a SIN vector containing the green fluorescent protein gene under the control of the internal CMV promoter transduced neurons as efficiently as a wild-type vector. Interestingly, a wild-type vector without an internal promoter also successfully transduced neurons in the brain, indicating that the HIV-1 LTR promoter is transcriptionally active in neurons even in the absence of Tat. Furthermore, injection of viruses into the subretinal space of the rat eye showed that wild-type vector transduced predominantly retinal pigment epithelium and photoreceptor cells, while SIN vector was able to transduce other types of retinal cells, including bipolar, Müller, horizontal, and amacrine cells. This finding suggests that the HIV-1 LTR can negatively influence the internal CMV promoter in some cell types. SIN HIV vectors should be safer for gene therapy, and they also have broader applicability as a means of high-level gene transfer and expression in nondividing cells.


Subject(s)
Genetic Vectors , HIV-1/genetics , Animals , Cytomegalovirus/genetics , Female , HIV Long Terminal Repeat , Promoter Regions, Genetic , Rats , Rats, Inbred F344 , Transcription, Genetic
12.
Proc Natl Acad Sci U S A ; 95(5): 2603-8, 1998 Mar 03.
Article in English | MEDLINE | ID: mdl-9482933

ABSTRACT

Bcl-xL suppresses apoptotic cell death induced by diverse stimuli in cell lines in vitro. To examine the mechanism by which axotomized cholinergic neurons die in vivo, lentiviral vectors expressing Bcl-xL, human nerve growth factor (hNGF), or green fluorescent protein were injected into the septum 3 weeks before transection of the fimbria fornix. Three weeks after transection, Bcl-xL- and hNGF-injected animals showed significantly higher numbers of spared cholinergic neurons compared with control (green fluorescent protein) injected animals. These results provide evidence that adult axotomized cholinergic neurons die of apoptotic death that can be prevented by local delivery of hNGF or intracellular delivery of Bcl-xL.


Subject(s)
Gene Transfer Techniques , Nerve Growth Factors/biosynthesis , Neurons/physiology , Prosencephalon/physiology , Proto-Oncogene Proteins c-bcl-2/physiology , Animals , Apoptosis , Axotomy , Cell Differentiation , Cell Line , Cell Survival , Cloning, Molecular , Female , Genetic Vectors , Green Fluorescent Proteins , Humans , Immunohistochemistry , Kidney , Lentivirus , Luminescent Proteins/biosynthesis , Neurons/cytology , PC12 Cells , Polymerase Chain Reaction , Prosencephalon/cytology , Proto-Oncogene Proteins c-bcl-2/biosynthesis , Rats , Rats, Inbred F344 , Recombinant Proteins/biosynthesis , Transfection , bcl-X Protein
13.
Nat Genet ; 17(3): 314-7, 1997 Nov.
Article in English | MEDLINE | ID: mdl-9354796

ABSTRACT

Successful gene therapy approaches will require efficient gene delivery and sustained expression of the transgene in recipients. A variety of methods, ranging from direct DNA delivery to infection with recombinant viruses containing foreign genes, have been developed, but they all have some major limitations that restrict their utility. We have described a human lentiviral (HIV)-based vector that can transduce non-dividing cells in vitro and deliver genes in vivo. With this vector, expression of transgenes in the brain has been detected for more than six months--the longest period tested so far. Because lentiviral vectors are pseudotyped with vesicular stomatitis virus G glycoprotein (VSVG; ref. 8), they can transduce a broad range of tissues and cell types. We now describe the ability of lentiviral vectors to introduce genes directly into liver and muscle. Sustained expression of green fluorescent protein (GFP), used as a surrogate for therapeutic protein, can be observed for more than 22 weeks in the liver. Similar long-term expression (more than eight weeks) was observed in transduced muscle. In contrast, little or no GFP could be detected in liver or muscle transduced with the Moloney murine leukaemia virus (M-MLV), a prototypic retroviral based vector. At a minimum, 3-4% of the total liver tissue was transduced by a single injection of 1-3 x 10(7) infectious units (I.U.) of recombinant HIV vector. Furthermore, no inflammation of recruitment of lymphocytes could be detected at the site of injection. Animals previously transduced with a lentiviral vector can be efficiently re-infected with lentiviral vectors. Additionally, we show that the requirement for lentiviral accessory proteins to establish efficient transduction in vivo is tissue dependent.


Subject(s)
Genetic Vectors/genetics , Genetic Vectors/pharmacology , Lentivirus/genetics , Liver/virology , Membrane Glycoproteins , Muscles/virology , Animals , Brain/virology , CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , Female , Genetic Therapy/methods , Green Fluorescent Proteins , HIV/genetics , Humans , Inflammation/virology , Liver/immunology , Luminescent Proteins/genetics , Luminescent Proteins/metabolism , Moloney murine leukemia virus/genetics , Muscles/immunology , Rats , Rats, Inbred F344 , Rats, Nude , Viral Envelope Proteins/genetics
14.
J Virol ; 71(9): 6641-9, 1997 Sep.
Article in English | MEDLINE | ID: mdl-9261386

ABSTRACT

The identification of monogenic and complex genes responsible for neurological disorders requires new approaches for delivering therapeutic protein genes to significant numbers of cells in the central nervous system. A lentivirus-based vector capable of infecting dividing and quiescent cells was investigated in vivo by injecting highly concentrated viral vector stock into the striatum and hippocampus of adult rats. Control brains were injected with a Moloney murine leukemia virus, adenovirus, or adeno-associated virus vector. The volumes of the areas containing transduced cells and the transduced-cell densities were stereologically determined to provide a basis for comparison among different viral vectors and variants of the viral vector stocks. The efficiency of infection by the lentivirus vector was improved by deoxynucleoside triphosphate pretreatment of the vector and was reduced following mutation of integrase and the Vpr-matrix protein complex involved in the nuclear translocation of the preintegration complex. The lentivirus vector system was able to efficiently and stably infect quiescent cells in the primary injection site with transgene expression for over 6 months. Triple labeling showed that 88.7% of striatal cells transduced by the lentivirus vector were terminally differentiated neurons.


Subject(s)
Gene Transfer Techniques , Genetic Vectors , Lentivirus , Neurons/metabolism , Adult , Animals , Biological Transport , Cell Line, Transformed , Female , Gene Expression , Genes, Reporter , Genetic Vectors/immunology , Green Fluorescent Proteins , Humans , Lentivirus/genetics , Lentivirus/immunology , Luminescent Proteins/genetics , Neurons/cytology , Rats , Rats, Inbred F344 , Transformation, Genetic , Transgenes , beta-Galactosidase/genetics
15.
Zentralbl Neurochir ; 58(4): 187-91, 1997.
Article in German | MEDLINE | ID: mdl-9487656

ABSTRACT

Case report of a 29-year-old woman with an psammomatoid ossifying fibroma of the left frontal sinus. Headache was the presenting clinical symptom. The tumor and its intracranial extension were identified by computed tomography and magnetic resonance tomography. Through a two-step combined neuro-rhinosurgical operation the tumor could be completely removed. Ossifying fibroma is a benign tumor mostly affecting the mandible and maxilla. A more aggressive approach may be more beneficial than expectant observation or curettage in the initial management of this benign neoplasm. Because of the unusual location of this rare entity the case history is published and differential diagnostic and therapeutical implications are discussed.


Subject(s)
Brain Neoplasms/secondary , Brain Neoplasms/surgery , Fibroma, Ossifying/surgery , Frontal Sinus , Paranasal Sinus Neoplasms/surgery , Adult , Brain Neoplasms/diagnosis , Brain Neoplasms/pathology , Female , Fibroma, Ossifying/diagnosis , Fibroma, Ossifying/pathology , Headache , Humans , Magnetic Resonance Imaging , Paranasal Sinus Neoplasms/diagnosis , Paranasal Sinus Neoplasms/pathology , Tomography, X-Ray Computed
16.
Proc Natl Acad Sci U S A ; 93(21): 11382-8, 1996 Oct 15.
Article in English | MEDLINE | ID: mdl-8876144

ABSTRACT

We describe the construction of a safe, replication-defective and efficient lentiviral vector suitable for in vivo gene delivery. The reverse transcription of the vector was found to be a rate-limiting step; therefore, promoting the reaction inside the vector particles before delivery significantly enhanced the efficiency of gene transfer. After injection into the brain of adult rats, sustained long-term expression of the transgene was obtained in the absence of detectable pathology. A high proportion of the neurons in the areas surrounding the injection sites of the vector expressed the transduced beta-galactosidase gene. This pattern was invariant in animals sacrificed several months after a single administration of the vector. Transduction occurs by integration of the vector genome, as it was abolished by a single amino acid substitution in the catalytic site of the integrase protein incorporated in the vector. Development of clinically acceptable derivatives of the lentiviral vector may thus enable the sustained delivery of significant amounts of a therapeutic gene product in a wide variety of somatic tissues.


Subject(s)
Brain/metabolism , Gene Transfer Techniques , Genetic Vectors , Lentivirus/genetics , Neurons/metabolism , Virus Integration , beta-Galactosidase/biosynthesis , Animals , Animals, Genetically Modified , Brain/cytology , Cell Line , Cytomegalovirus/genetics , Genes, Reporter , Genes, gag , Genes, pol , Humans , Kidney , Lac Operon , Neurons/cytology , Rats , Safety
17.
Science ; 272(5259): 263-7, 1996 Apr 12.
Article in English | MEDLINE | ID: mdl-8602510

ABSTRACT

A retroviral vector system based on the human immunodeficiency virus (HIV) was developed that, in contrast to a murine leukemia virus-based counterpart, transduced heterologous sequences into HeLa cells and rat fibroblasts blocked in the cell cycle, as well as into human primary macrophages. Additionally, the HIV vector could mediate stable in vivo gene transfer into terminally differentiated neurons. The ability of HIV-based viral vectors to deliver genes in vivo into nondividing cells could increase the applicability of retroviral vectors in human gene therapy.


Subject(s)
Gene Transfer Techniques , Genetic Vectors , HIV/genetics , Amino Acid Sequence , Animals , Base Sequence , Brain/cytology , Brain/virology , Cell Division , Cells, Cultured , Female , Genetic Therapy , HIV/physiology , HeLa Cells , Humans , Macrophages/cytology , Macrophages/virology , Molecular Sequence Data , Neurons/cytology , Neurons/virology , Plasmids , Rats , Transfection , Virus Integration
18.
Hum Mol Genet ; 5 Spec No: 1397-404, 1996.
Article in English | MEDLINE | ID: mdl-8875243

ABSTRACT

Gene therapy is a new method with potential for treating a broad range of acquired and inherited neurologic diseases, where the causative gene defect or deletion has been identified. In addition to gene replacement the application of gene products that reduce cellular dysfunction or death represent new therapeutic options. Gene transfer techniques to express novel proteins using different viral vectors in vitro and in vivo, as well as animal models and human trials will be reviewed in this article. We will focus on a new lentiviral vector as a recent gene transfer method and degenerative disorders of the CNS, and their related model systems.


Subject(s)
Central Nervous System/metabolism , Genetic Therapy , Adenoviridae/genetics , Animals , Dependovirus/genetics , Disease Models, Animal , Forecasting , Genetic Vectors , Herpesviridae/genetics , Humans , Neurons/metabolism , Retroviridae/genetics
20.
J Neurochem ; 65(5): 1997-2005, 1995 Nov.
Article in English | MEDLINE | ID: mdl-7595483

ABSTRACT

Expression of receptors for the neuropeptide somatostatin was investigated in vitro in rat and human astrocytes, glioma cell lines, and solid human glial tumors that were all immunopositive for the astrocytic marker glial fibrillary acidic protein. After affinity labelling with a peptide-gold conjugate of known biological activity, somatostatin-binding sites could be visualized at the light-and electron-microscopic level on the surface of glial cells. Glioma cells were generally labeled more strongly than were normal astrocytes and preferentially bound the ligand at their processes and not at their somata as were normal cells. Somatostatin transmembrane receptor (SSTR) subtype expression was probed by reverse transcription-polymerase chain reaction: In rat and human cortical astrocytes and in one glioma cell line (U 118), a pattern of three subtypes (SSTR-1, SSTR-2, and SSTR-4) was detected, whereas, in all other glioma cell lines and in six solid glial tumors investigated, the SSTR-2 subtype was relatively stronger, expressed either alone or in combination with SSTR-1; sometimes SSTR-3 or SSTR-4 was demonstrated in clearly reduced amounts. In astrocytes and gliomas, somatostatin reduced the levels of cyclic AMP elicited by the adenylate cyclase activator forskolin indicating that at least one of the receptor subtypes is negatively linked to adenylate cyclase. In contrast to other cell types, somatostatin did not inhibit the basal or the fetal calf serum-stimulated proliferation of astrocytes, glioma cell lines, or glial tumors in culture. Thus, strong SSTR-2 subtype expression characterizes glial tumors, but somatostatin is ineffective in inhibiting their growth.


Subject(s)
Astrocytes/metabolism , Glioma/metabolism , Receptors, Somatostatin/metabolism , Animals , Astrocytes/cytology , Base Sequence , Cell Division/drug effects , Cells, Cultured , Cyclic AMP/metabolism , Glioma/pathology , Humans , Molecular Probes/genetics , Molecular Sequence Data , RNA, Messenger/metabolism , Rats , Somatostatin/metabolism , Somatostatin/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...